Sensus Healthcare, Inc - SRTS STOCK NEWS

On April 25, 2023, Sensus Healthcare, Inc. (SRTS) announced a conference call scheduled for May 3, 2023, at 4:30 PM ET to discuss first-quarter 2023 financial results. During this call, management will also provide a business update and discuss ongoing and upcoming milestones. Participants can pre-register for the call to receive a unique dial-in number, allowing them to bypass the operator. The live webcast will be accessible through the company’s website, with a replay available until June 3, 2023. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, offering innovative devices for skin cancer and aesthetic procedures.

Sensus Healthcare (Nasdaq:SRTS) has launched Sensus Cloud, a groundbreaking cloud-based platform designed for asset and EMR management in healthcare. This platform allows healthcare providers to collect real-time data from medical devices, streamlining patient monitoring and treatment management.

Key features include an intuitive interface for tracking patient treatment history, device usage, and service details, alongside predictive analytics for proactive care management. The system ensures data security with multi-factor authentication and encryption, enhancing user and patient data protection. Sensus Healthcare will showcase this innovative platform at the American Academy of Dermatology Annual Meeting from March 17-19, 2023.

Sensus Healthcare reported a 65% increase in full-year revenues, totaling $44.5 million for 2022, driven by increased product demand. Fourth-quarter revenues reached $13.1 million, slightly up from $13.0 million year-over-year. However, net income fell to $2.8 million ($0.17 per share) compared to $5.3 million ($0.32 per share) in Q4 2021, largely due to rising manufacturing costs.

The company ended 2022 with $25.5 million in cash and no debt, with expectations of continued growth and a focus on expanding aesthetic product offerings in 2023.

Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on February 9, 2023, at 4:30 p.m. ET to discuss its financial results for Q4 and the full year 2022. The call will include a business update and insights on recent and upcoming milestones. Investors can access the call through a dial-in number or via a live webcast. A replay of the call will be available until March 9, 2023. Sensus specializes in non-invasive medical devices that utilize proprietary low-energy X-ray technology for treating oncological conditions, enhancing patient quality of life.

Sensus Healthcare (Nasdaq: SRTS) has announced key promotions and appointments within its management team to enhance growth and operational efficiency. Promoted to COO is Maggie Martinez, who has been with the company for nine years. Emiliano Sosa becomes CTO, focusing on engineering and technology expansion. Stephanie Tipton is now VP of Marketing, while Sean Delaney is appointed VP of Regulatory and Quality Assurance, and Wayne Lura becomes VP of Aesthetic Sales. These changes are part of Sensus' aggressive business strategy aimed at improving customer support and expanding market reach.

Sensus Healthcare, Inc. (SRTS) reports strong preliminary revenues for Q4 2022 expected to exceed $13 million and an estimated $44 million for the full year, marking 60% growth over 2021. The fourth quarter revenues will also include over $500,000 from the aesthetics segment. Profitability is expected for both the quarter and the year. Plans for 2023 include expanding the domestic sales force, increasing trade show presence, and geographic expansion in the EU and Latin America.